- Arcosa (NYSE:ACA) has agreed to be acquired by CRH in an all-cash deal valued at about $8.5b.
- The transaction is subject to shareholder and regulatory approvals before closing.
- Arcosa will become part of CRH, one of the largest building materials companies globally, if the deal is completed.
Arcosa enters this proposed acquisition with its stock at $144.34, after returns of 8.4% over the past week and 19.5% over the past month. The shares are up 35.2% year to date and 68.9% over the past year, with longer term gains of 96.0% over three years and 149.3% over five years. Those moves frame how the market has been pricing Arcosa ahead of this landmark deal.
For current and prospective investors in Arcosa, this pending transaction shifts the focus toward deal terms, timing, and approval risk. The all-cash structure, the premium implied by the $8.5b valuation, and Arcosa’s future role inside CRH are likely to be central points to watch as new information emerges.
Stay updated on the most important news stories for Arcosa by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Arcosa.
We've flagged 1 risk for Arcosa. See which could impact your investment.
Quick Assessment
- ⚖️ Price vs Analyst Target: Arcosa trades at US$144.34, which is very close to the US$145.50 analyst price target range of US$140 to US$150.
- ❌ Simply Wall St Valuation: The stock is described as trading 176.8% above estimated fair value, which signals a rich valuation.
- ✅ Recent Momentum: A 19.5% return over the last 30 days shows strong short term momentum into the proposed US$8.5b cash deal.
There's only one way to know the right time to buy, sell or hold Arcosa. Head to Simply Wall St's company report for the latest analysis of Arcosa's Fair Value.
Key Considerations
- 📊 With Arcosa set to be acquired for cash, the focus shifts from long term growth to how closely the share price tracks the agreed deal value and any spread that opens up.
- 📊 Watch the relationship between the US$144.34 price, the implied deal valuation, and the analyst target range to gauge how much approval or timing risk the market is pricing in.
- ⚠️ The flagged risk around a high level of debt is worth monitoring, as it could influence regulatory reviews or perceptions of balance sheet strength inside CRH.
Dig Deeper
For the full picture including more risks and rewards, check out the complete Arcosa analysis. Alternatively, you can check out the community page for Arcosa to see how other investors believe this latest news will impact the company's narrative.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com